HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

paragon

toluidine blue-basic fuscin stain
Networked: 42 relevant articles (1 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Harrington, Robert A: 11 articles (12/2010 - 02/2002)
2. Newby, L Kristin: 8 articles (12/2010 - 02/2002)
3. Califf, Robert M: 8 articles (10/2007 - 02/2002)
4. Topol, Eric J: 7 articles (10/2004 - 02/2002)
5. Moliterno, David J: 6 articles (02/2008 - 07/2002)
6. Armstrong, Paul W: 6 articles (10/2007 - 02/2002)
7. Granger, Christopher B: 6 articles (10/2007 - 07/2002)
8. Mahaffey, Kenneth W: 4 articles (12/2010 - 02/2002)
9. Pieper, Karen S: 4 articles (12/2010 - 08/2002)
10. Rao, Sunil V: 3 articles (12/2010 - 04/2003)

Related Diseases

1. Myocardial Infarction
02/01/2002 - "Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. "
12/01/2007 - "The initial studies (PRISM, PRISM-PLUS, PURSUIT, PARAGON, CAPTURE, GUSTO IV-ACS) were performed at the end of the 1990s and universally showed a significant reduction in an endpoint combining death and myocardial infarction, especially in patients with an elevation of troponin and treated by angioplasty. "
04/01/2000 - "Lamifiban is a short-acting, renally excreted IIb/IIIa antagonist that was found in post hoc analyses of the Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON A) study to reduce the 30-day incidence of death or myocardial infarction by 40% when plasma concentrations of 18 to 42 ng/mL were achieved. "
07/01/2000 - "Patient understanding of clinical trial details was assessed on 2 occasions (10 +/- 4 and 24 +/- 3 hours after randomization) in 20 patients enrolled for randomized investigation of pharmacotherapy for unstable angina pectoris or non-Q-wave myocardial infarction in the Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organized Network (PARAGON B) and Organization to Assess Strategies in Ischemic Syndromes (OASIS-2) trials. "
02/01/1999 - "In trials in patients with non-Q wave myocardial infarction (MI) or unstable angina pectoris (PARAGON A and the Canadian Lamifiban Study), the incidence of clinical events at 30 days in patients receiving lamifiban (1 to 5 microg/min) was not significantly different from that in patients receiving aspirin plus heparin or aspirin alone. "
2. Acute Coronary Syndrome
3. Unstable Angina
07/01/2000 - "Patient understanding of clinical trial details was assessed on 2 occasions (10 +/- 4 and 24 +/- 3 hours after randomization) in 20 patients enrolled for randomized investigation of pharmacotherapy for unstable angina pectoris or non-Q-wave myocardial infarction in the Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organized Network (PARAGON B) and Organization to Assess Strategies in Ischemic Syndromes (OASIS-2) trials. "
10/01/2007 - "Accordingly, we evaluated 26,466 NSTE ACS patients from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb), Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON) A and B trials to ascertain the timing of adverse events. "
08/20/2002 - "The 4 trials were Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb, GUSTO-III, Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON-A). "
08/01/1998 - "Glycoprotein IIb/IIIa receptor antagonists were then researched in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC), the c7E3 Fab Antiplatelet Therapy in Unstable Refractory angina (CAPTURE), the Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON) and the Platelet Receptor Inhibition of Ischemic Syndrome Management in Patients Limited to Unstable Angina Signs and Symptoms (PRISM-PLUS) studies, shifting the attention to the platelet. "
02/01/1999 - "A large phase III trial (PARAGON B) is under way comparing lamifiban plus aspirin and heparin with standard aspirin and heparin therapy in patients with non-Q wave MI or unstable angina pectoris. "
4. Diastolic Heart Failure
5. Neoplasm Metastasis (Metastasis)

Related Drugs and Biologics

1. Troponin
2. Glycoproteins (Glycoprotein)
3. eptifibatide (Integrilin)
4. lamifiban
5. Heparin (Liquaemin)
6. Platelet Membrane Glycoprotein IIb
7. MB Form Creatine Kinase
8. Troponin I
9. Streptokinase
10. Myoglobin

Related Therapies and Procedures

1. Angioplasty (Angioplasty, Transluminal)
2. Drug Therapy (Chemotherapy)
3. Lenses
4. Contact Lenses
5. Laser In Situ Keratomileusis (LASIK)